A
Alopexx
ALPXFiledAlopexx, Inc. · NYSE American (proposed) · Clinical-stage biotechnology · Report filing 2026/08/17 · SEC checked 2026-10-07
DAILY SEC UPDATES-1/A analysed from the latest filing
As of the linked September 17, 2026 S-1/A, Alopexx has not completed its proposed IPO and is developing clinical-stage PNAG-targeted immune therapeutics.
One-minute decisionBASIC RESEARCHSource completeness · 90%
High-risk biotech watch: funded milestones improve, but no product revenue and going-concern risk dominate
Alopexx filed 3.0M shares at $10–$12 under ALPX; NYSE American approval, SEC effectiveness and the listing date remain pending.
Capital destination
$30.1MNo estimate is substituted for missing offer terms.
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · S-1/A ↗Capital destination
$30.1MNo estimate is substituted for missing offer terms.
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · S-1/A ↗BOOKRUNNERS / LEAD UNDERWRITERSRepresentative of the underwriters
PRELIMINARY- 1ThinkEquity——
Dilution and valuation
IPO priceAwaiting verification
Basic post-offer8.349M
Fully diluted sharesAwaiting verification
Value$91.8M
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer | 8.349M | $91.8M | +56.1% |
Basic-price scenario
A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.
Check the source · S-1/A ↗Daniel Vlock
56.3%CEO Daniel Vlock retains majority ownership after the base offering.
Base post-offer ownership · 2026/08/17
Issuer expects to qualify as an NYSE American controlled company
One disclosed holder; not a complete ownership distribution.Check the source · S-1/A ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| Other holders | +180 days Existing pool · non-executive existing shares | Other holders · Other stockholders and option holders · Not yet published — awaiting the effective or final prospectus. · 180-day lock-up, subject to ThinkEquity consent |
Basis and evidence
Other holders
Other holders · Other stockholders and option holders · Not yet published — awaiting the effective or final prospectus. · 180-day lock-up, subject to ThinkEquity consent
Lock-up / shares eligible for future sale ↗Financial quality
| Calculation | Reported value | Reference |
|---|---|---|
| FY2025 net loss | $(2.608M) | 14.8% narrower |
Latest filing update
Loading saved filing update…
No product is approved and clinical outcomes are binary and uncertain.
- Potential impact
- Very high
- Monitor
- SEC effectiveness and NYSE approval
- Evidence
- S-1/A · 2026/08/17 ↗
DocumentS-1/A✓ Verified against the SEC source · Latest SEC amendment
Filed2026/08/172 public filings identified
Research updated2026/08/17SEC EDGAR
Evidence coverage90%Range, shares, ownership, use of proceeds and March financials filed
What remains missing10% of the evidence set remains unresolved. This may affect unconfirmed pricing, valuation, dilution or supply conclusions; no missing term is estimated.
View the filing's actual first page ＋
